Gastroenterology

Keeping Up with Gastroenterology Research: IBD, Hepatology, Endoscopy, and GI Oncology

Gastroenterology and hepatology encompass some of the most therapeutically dynamic areas in medicine. IBD biologics have multiplied and diversified. NAFLD/MASLD has its first approved pharmacotherapy. Colorectal cancer screening guidelines have shifted. Endoscopic techniques continue advancing. This guide covers practical strategies for gastroenterologists to stay current across this breadth.

Core journals for gastroenterologists

Gastroenterology — AGA flagship, highest impact GI journal
Gut — BSG/BMJ, particularly strong on IBD and GI oncology
The American Journal of Gastroenterology (AJG) — ACG flagship, clinically oriented
Hepatology — AASLD flagship, essential for hepatologists
Journal of Hepatology — EASL journal, important for liver disease evidence from European trials
Gastrointestinal Endoscopy — procedural and endoscopic outcomes literature
Clinical Gastroenterology and Hepatology (CGH) — AGA practice-oriented journal

IBD biologics: the most complex therapeutic landscape in GI

Inflammatory bowel disease therapeutics have become among the most complex in medicine. Crohn's disease and ulcerative colitis now have more than a dozen approved biologic and small molecule options across five distinct mechanisms of action:

Anti-TNF: infliximab, adalimumab, certolizumab, golimumab
Anti-integrin: vedolizumab (gut-selective), natalizumab (CNS risk)
Anti-IL-12/23 and anti-IL-23: ustekinumab, risankizumab, mirikizumab, guselkumab (in trials)
JAK inhibitors: tofacitinib, upadacitinib, filgotinib
S1P modulator: ozanimod, etrasimod

Head-to-head trial data — SEAVUE (adalimumab vs. ustekinumab in CD), VARSITY (vedolizumab vs. adalimumab in UC), SELECT (upadacitinib) — are reshaping therapy sequencing and positioning. Gastroenterologists managing IBD require ongoing surveillance of comparative effectiveness data and emerging combination therapy evidence.

Emerging area: Combination biologic therapy in IBD — pairing a vedolizumab with an anti-TNF or anti-IL-23 — is under active investigation. Early data from the VEGA and EXPLORER trials suggest potential synergy. This represents a major potential practice change pending larger confirmatory trials.

NAFLD/MASLD: the renamed and newly treatable condition

The 2023 nomenclature change from NAFLD to MASLD (metabolic dysfunction-associated steatotic liver disease) reflects the field's evolution toward a metabolic, rather than purely hepatic, framework. More importantly, resmetirom (Rezdiffra) received FDA approval in 2024 as the first approved pharmacotherapy for noncirrhotic MASH — a landmark change in a disease that previously had no approved treatments. Key surveillance points:

Resmetirom efficacy and safety data — MAESTRO-NASH trial results and post-marketing data
GLP-1 and GIP/GLP-1 agonists (semaglutide, tirzepatide) in MASH — ESSENCE and SURMOUNT-4 hepatic endpoint data
Non-invasive MASH staging — FIB-4, liver stiffness measurement, and their role in replacing liver biopsy
MASH screening protocols — who should be assessed for advanced fibrosis?

Colorectal cancer screening: guideline changes with practice implications

The USPSTF updated CRC screening recommendations in 2021, lowering the initiation age to 45. The ACS made the same change in 2018. The practical implementation — how to counsel patients aged 45 to 49 about modality choice, how to integrate primary CRC screening colonoscopy with colonoscopy demand from other indications — remains an area of active practice evolution. The ACG and AGA have published detailed implementation guidance.

Hepatology: the viral hepatitis endgame and what comes next

Hepatitis C has been effectively cured in the majority of patients in high-income countries through direct-acting antivirals. Hepatitis B cure remains elusive but is the focus of significant ongoing research (capsid assembly modulators, RNAi therapeutics, PEG-interferon combinations). Current hepatology literature priorities:

HBV surface antigen loss — emerging therapeutic approaches and trial data
Liver transplant outcomes — immune tolerance protocols, hepatitis E in immunosuppressed recipients
Portal hypertension management — transjugular intrahepatic portosystemic shunt (TIPS) timing, beta-blocker optimization, carvedilol data
Alcohol-associated liver disease — severity assessment and evolving treatment protocols including corticosteroids and emerging agents

Advanced endoscopy: the technology treadmill

Endoscopic techniques advance faster than most gastroenterologists can track through journals alone. Key areas requiring active surveillance:

AI-assisted colonoscopy — adenoma detection rate improvement with computer-aided detection (CADe)
Endoscopic resection — ESD vs. EMR for large flat polyps, evidence for follow-up intervals
EUS-guided interventions — cyst drainage, biliary access, tumor ablation evolving evidence
Peroral endoscopic myotomy (POEM) — expanding applications and comparative data vs. Heller myotomy

Conference priorities in gastroenterology

DDW (Digestive Disease Week) (May/June) — the largest GI conference, covers full scope of gastroenterology and hepatology
UEGW (United European Gastroenterology Week) (October) — European equivalent, important for IBD and liver disease trial data
AASLD Liver Meeting (November) — the premier hepatology conference
ACG Annual Scientific Meeting (October/November) — American College of Gastroenterology, clinically oriented

Get the most important papers in your specialty every week

MDInformed curates the five most clinically relevant papers from 35 million publications and delivers them as a structured digest — free forever.

Join the waitlist →